17 December 2015 - Astellas Pharma Australia has announced that the indication for Xtandi (enzalutamide) has been extended by the TGA to include the treatment of patients with metastatic castration-resistant prostate cancer following the failure of androgen deprivation therapy in whom chemotherapy is not yet indicated.

For more details, go to: http://www.firstwordpharma.com/node/1342106#axzz3ujLNz2xu